In patients with chronic coronary syndrome and an indication for oral anticoagulation, whether continuation of antiplatelet therapy in the initial phase after percutaneous coronary intervention is appropriate in Western populations with high atherothrombotic risk was previously unclear. The AQUATIC trial now shows that continuation of antiplatelet therapy increases the risk of both bleeding and ischaemic events in these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Vrints, C. et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45, 3415–3537 (2024).
Parker, W. A. E. et al. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. Eur. Heart J. Suppl. 22 (Suppl. M), M26–M34 (2020).
Rashedi, S. et al. Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials. J. Am. Coll. Cardiol. 85, 1189–1203 (2025).
Lemesle, G. et al. Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2507532 (2025).
Parker, W. A. E. & Storey, R. F. Antithrombotic therapy for patients with chronic coronary syndromes. Heart 107, 925–933 (2021).
Sumaya, W. et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI study). Thromb. Haemost. 118, 1250–1256 (2018).
Ducrocq, G. et al. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention 11, 737–745 (2015).
Parker, W. A. E. Evolution of coronary stents: innovations, antithrombotic strategies and future directions. Heart 111, 753–762 (2025).
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017).
Sammut, M. A. et al. Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel. Platelets 36, 2507037 (2025).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W.A.E.P. has received consulting fees and research support from AstraZeneca. R.F.S. has received research grants from AstraZeneca and CytoSorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, AstraZeneca, Boehringer Ingelheim/Lilly, Bristol Myers Squibb, Chiesi, Cytosorbents, Idorsia/Viatris, Johnson & Johnson, Novo Nordisk, PhaseBio and Tabuk.
Rights and permissions
About this article
Cite this article
Parker, W.A.E., Storey, R.F. AQUATIC findings sink antiplatelet therapy for patients with chronic coronary syndrome requiring oral anticoagulants. Nat Rev Cardiol 22, 921–922 (2025). https://doi.org/10.1038/s41569-025-01224-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41569-025-01224-0
